[{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Bach Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"PNT2004","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pro-doxorubicin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"CanProbe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium\u2013177 Octreotate","moa":"SSRT2","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ POINT"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Kinectrics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ IONETIX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ IONETIX Corporation"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lu-177","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ Belgian Nuclear Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Belgian Nuclear Research Center"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lu-177-PSMA-I&T","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Lantheus Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holdings"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"AdvanCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"212Pb-ADVC001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Athebio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"DARPin-targeted Radioligand","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ POINT Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Point Biopharma \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"[Lu-177]-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Point Biopharma"}]
Find Clinical Drug Pipeline Developments & Deals by Point Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
